Evidence map›Paper›PMID 30040046›Full record

ReviewRadiation research2018

Defenses against Pro-oxidant Forces - Maintenance of Cellular and Genomic Integrity and Longevity.

David Murray, Razmik Mirzayans, William H McBride

Open access · bronzeAbstract readReview
In one paragraph

Review in Radiation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Oxidative Stress in Cancer.Cancer cell · 2020
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

David Murraya   Department of Oncology, Division of Experimental Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Canada.
Razmik Mirzayansa   Department of Oncology, Division of Experimental Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Canada.
William H McBrideb   Department of Radiation Oncology, University of California, Los Angeles (UCLA), Los Angeles, California.
University of Alberta · CAUniversity of California, Los Angeles · US

Funding

UCLA Center for Biological RadioprotectorsU19AI067769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHUTE, JOHN P, MCBRIDE, WILLIAM H. · 2005 to 2019
$44.6M
Organ-specific NRF2-mediated protein signatures of radiation exposure & tissue daR01AI101888 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WHITELEGGE, JULIAN P · 2012 to 2016
$1.9M
NIAID NIH HHS R01 AI101888NIAID NIH HHS U19 AI067769
6 · The paper itself

Abstract

There has been enormous recent progress in understanding how human cells respond to oxidative stress, such as that caused by exposure to ionizing radiation. We have witnessed a significant deciphering of the events that underlie how antioxidant responses counter pro-oxidant damage to key biological targets in all cellular compartments, including the genome and mitochondria. These cytoprotective responses include: 1. The basal cellular repertoire of antioxidant capabilities and its supporting cast of facilitator enzymes; and 2. The inducible phase of the antioxidant response, notably that mediated by the Nrf2 transcription factor. There has also been frenetic progress in defining how reactive electrophilic species swamp existing protective mechanisms to augment DNA damage, events that are embodied in the cellular "DNA-damage response", including cell cycle checkpoint activation and DNA repair, which occur on a time scale of hours to days, as well as the implementation of cellular responses such as apoptosis, autophagy, senescence and reprograming that extend the time period of damage sensing and response into weeks, months and years. It has become apparent that, in addition to the initial oxidative insult, cells typically undergo further waves of secondary reactive oxygen/nitrogen species generation, DNA damage and signaling and that these may reemerge long after the initial events have subsided, probably being driven, at least in part, by persisting DNA damage. These reactive oxygen/nitrogen species are an integral part of the pathological consequences of radiation exposure and may persist across multiple cell divisions. Because of the pervasive nature of oxidative stress, a cell will manifest different responses in different subcellular compartments and to different levels of stress injury. Aspects of these compartmentalized responses can involve the same proteins (such as ATM, p53 and p21) but in different functional guises, e.g., in cytoplasmic versus nuclear responses or in early- versus late-phase events. Many of these responses involve gene activation and new protein synthesis as well as a plethora of post-translational modifications of both basal and induced response proteins. It is these responses that we focus on in this review.

Indexed as

Genomic InstabilityLongevityAnimalsAntioxidantsAtaxia Telangiectasia Mutated ProteinsCarcinoma, Non-Small-Cell LungCell Physiological PhenomenaCyclin-Dependent Kinase Inhibitor p21DNA-(Apurinic or Apyrimidinic Site) LyaseDNA DamageDNA RepairHumansLung NeoplasmsNF-E2-Related Factor 2Oxidative StressProtein BiosynthesisAntioxidantsAPEX1 protein, humanAtaxia Telangiectasia Mutated ProteinsATM protein, humanCyclin-Dependent Kinase Inhibitor p21DNA-(Apurinic or Apyrimidinic Site) LyaseNFE2L2 protein, humanNF-E2-Related Factor 2Reactive Oxygen SpeciesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID30040046
PMCPMC6203329
OpenAlexW2884773104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.